Pulse Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pulse Biosciences, Inc. (PLSE) on April 9, 2026, regarding events occurring on April 8, 2026. The filing announces the appointment of Liane R. Teplitsky as Chief Operating Officer (COO), effective April 8, 2026. Ms. Teplitsky brings extensive experience in medical device commercialization and robotics, having previously served as CEO of Artedrone and held senior roles at Abbott Laboratories, St. Jude Medical, and Zimmer Biomet.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, or debt metrics for the Company. The only financial data provided relates to the compensation package for the new COO:
- Base Salary: $525,000 annually.
- Target Bonus: 70% of annual base salary ($367,500), subject to performance objectives.
- Stock Option Grant: 700,000 shares at an exercise price of $19.06 per share (closing price on April 8, 2026).
- Restricted Stock Units (RSUs): 200,000 units granted.
Material Changes
The primary material change is the addition of a new C-suite executive. The filing details a significant equity compensation structure tied to specific corporate milestones, including:
- Market Capitalization Targets: Vesting of options is contingent on the Company maintaining market caps of $2.0 billion, $3.0 billion, and $5.0 billion for 270 consecutive days.
- Revenue Targets: Vesting of both options and RSUs is contingent on achieving GAAP product revenue thresholds of $100 million, $200 million, and $300 million over twelve-month periods.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance or general outlook commentary. However, the performance-based vesting conditions imply management's strategic targets for future growth. The employment agreement is at-will with no specific term. There are no reported family relationships or related party transactions involving the new appointee.
Key Facts for Investor Verification
- Verify the Company's current market capitalization relative to the $2.0B, $3.0B, and $5.0B vesting thresholds.
- Review the Company's most recent 10-K or 10-Q to assess current GAAP product revenue against the $100M, $200M, and $300M vesting milestones.
- Confirm the dilution impact of the 700,000 stock options and 200,000 RSUs granted to the new COO.
- Monitor the press release (Exhibit 99.1) for additional strategic context regarding the appointment.